Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors

Bouhamama, Amine; Lame, Fabrice; Mastier, Charles; Cuinet, M.; Thibaut, Antoine; Beji, H.; Ricoeur, Alexis; Blay, Jean‐Yves; Pilleul, F.

doi:10.1007/s00270-019-02323-5

Cited by 25 publications

(36 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the so-called investigational therapies that are also alternative methods for achieving local control of the tumor include cryoablation, radiofrequency ablation, and high-intensity focused ultrasound [ 9 10 11 12 13 14 15 16 17 18 19 ]. Cryoablation has been shown to be effective in extra-abdominal fibromatosis [ 9 10 11 12 13 ]. Bouhamama et al [ 13 ] conducted the largest case series study on cryoablation: they treated 34 patients with desmoid fibromatosis and achieved resolution in up to 40% of cases and volume reduction in more than 95% of patients.…”

Section: Discussionmentioning

confidence: 99%

“…The volume of the viable tumor lesion was measured on the pre- and post-treatment MRI scans. Control of the major axis of the lesion was not considered as a criterion for treatment response due to the irregular morphology of this lesion and the fact that this parameter was not useful for differentiating sbetween active and non-active tumor areas [ 9 10 11 12 13 14 15 16 17 18 ].…”

Section: Methodsmentioning

confidence: 99%

“…Various treatment strategies and modalities have been proposed, including expectant management, surgery, radiation therapy, medical therapies, and isolated limb perfusion. Other methods of achieving local control of the disease are currently being investigated, including cryoablation [ 9 10 11 12 13 ], radiofrequency ablation [ 14 15 ] and high-intensity focused ultrasound ablation [ 16 17 18 ]. These therapies are in the early stages of clinical trials and retrospective studies with limited sample sizes that lack comparison with alternative therapies are the best sources of currently available evidence.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Percutaneous Microwave Ablation of Desmoid Fibromatosis

et al. 2021

View full text Add to dashboard Cite

Objective To demonstrate the feasibility of percutaneous microwave ablation in desmoid fibromatosis with respect to tumor volume control and improvement in the quality of life. Materials and Methods Twelve microwave ablations were performed in 9 patients with a histological diagnosis of desmoid fibromatosis between January 2010 and January 2019. The study population included 6 female and 3 male, with an age range of 21–76 years (mean = 46.6 years; standard deviation [SD] = 19.3 years). The mean major axis of the tumors was 10.9 cm (SD = 5.2 cm) and mean lesion volume was 212.7 cm 3 (SD = 213 cm 3 ). Their anatomical distribution was as follows: 3 lesions in the thigh, 2 in the gluteus, 2 in the leg and 2 in the periscapular region. We evaluated the reduction in tumor volume and improvement in the quality of life based on the Eastern Cooperative Oncology Group (ECOG) scale. Results An average tumor volume reduction of 70.4% (SD = 24.9) was achieved, while the quality of life (ECOG scale) improved in 88.9% of patients. Conclusion Percutaneous microwave ablation may potentially be a safe, effective, and promising technique for controlling tumor volume and improving the quality of life in patients with desmoid fibromatosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Percutaneous Microwave Ablation of Desmoid Fibromatosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The study met its primary endpoint with 86% of patients having non-progressive disease at the 12-month follow-up, reduced pain, and better functional status. We found an additional five retrospective case series including up to 34 patients, one prospective case series, and three case reports ( Table 4 ) [ 11 , 12 , 13 , 14 , 24 , 25 , 26 , 27 , 28 ]. Most of these studies evaluated the safety and efficacy of CA as a second- or third-line treatment in symptomatic or progressive EAD tumors.…”

Section: Discussionmentioning

confidence: 99%

“…In most cases, efficacy was evaluated using the RECIST criteria, TDT-V or ET-V measurements, and DFS rates. In up to 40% of cases, Bouhamama et al reported that complete treatment was not possible due to the proximity of critical anatomical structures and the treatment’s main objective being tumor debulking [ 27 ]. Havez et al reported that the DFS rate in a total of 13 patients (17 tumors) was stable at 82.3% at 6, 12, and 24 months [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Cryoablation of Extra-Abdominal Desmoid Tumors: A Single-Center Experience with Literature Review

et al. 2020

View full text Add to dashboard Cite

Cryoablation (CA) has gained popularity in the treatment of benign and malignant musculoskeletal tumors. While extra-abdominal desmoid (EAD) tumors are not malignant, they remain challenging to treat because of their high local recurrence rate. We reviewed all EAD tumors treated with CA at our institution between November 2012 and March 2020. Fourteen procedures were performed on nine females and one male (mean age, 33 ± 18 years) as either first-line (n = 4) or salvage therapy (n = 6) with curative intent (n = 8) or tumor debulking (n = 2). Mean tumor size was 63.6 cm3 (range, 3.4–169 cm3). Contrast-enhanced MRI was performed before treatment and at 3-, 6-, and 12-month follow-up. Treatment outcome was based on the change in enhanced tumor volume (ET-V). For curatively treated patients, the mean ET-V change was −97 ± 7%, −44 ± 143%, and +103 ± 312% at 3, 6, and 12 months, respectively. For debulking patients, the mean ET-V change was −98 ± 4%, +149 ± 364%, and +192 ± 353% at 3, 6, and 12 months, respectively. During a mean follow-up of 53.7 months (range, 12–83 months), one grade III and one grade IV complication were noted. We found CA to be safe and well tolerated in patients with EAD.

show abstract

Pain in desmoid‐type fibromatosis: Prevalence, determinants and prognosis value

Penel

Bonvalot

Deley

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

The aim of this study is to evaluate the prevalence, determinants and prognostic value of pain at diagnosis in patients with desmoid‐type fibromatosis (DF). We selected patients from the ALTITUDES cohort (NCT02867033), managed by surgery, active surveillance or systemic treatments, with pain assessment at diagnosis. Patients were invited to fill QLQ‐C30 questionnaire and Hospital Anxiety Depression Scale. Determinants were identified using logistic models. Prognostic value on event‐free survival (EFS) was evaluated using the Cox model. Overall, 382 patients were included in the current study (median age: 40.2 years; 117 men). The prevalence of pain was 36%, without significant difference according to first‐line treatment (P = .18). In the multivariate analysis, pain was significantly associated with tumor size >50 mm (P = .013) and tumor site (P < .001); pain was more frequent in the neck and shoulder locations (odds ratio: 3.05 [1.27‐7.29]). Pain at baseline was significantly associated with poor quality of life (P < .001), depression (P = .02), lower performance status (P = .03) and functional impairment (P = .001); we also observed a nonsignificant association with anxiety (P = .10). In the univariate analysis, baseline pain was associated with poor EFS; the 3‐year EFS was 54% in patients with pain compared to 72% in those without pain. After adjustment for sex, age, size and line of treatment, pain was still associated with poor EFS (hazard ratio: 1.82 [1.23‐2.68], P = .003). One third of recently diagnosed patients with DF experienced pain, especially those with larger tumors and neck/shoulder locations. Pain was associated with unfavorable EFS after adjustment for the confounders.

show abstract

Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors

Cited by 25 publications

References 35 publications

Percutaneous Microwave Ablation of Desmoid Fibromatosis

Percutaneous Microwave Ablation of Desmoid Fibromatosis

Cryoablation of Extra-Abdominal Desmoid Tumors: A Single-Center Experience with Literature Review

Pain in desmoid‐type fibromatosis: Prevalence, determinants and prognosis value

Contact Info

Product

Resources

About